HEADER VIRAL PROTEIN 29-MAR-20 7BRP TITLE CRYSTAL STRUCTURE OF THE 2019-NCOV MAIN PROTEASE COMPLEXED WITH TITLE 2 BOCEPREVIR COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3C-LIKE PROTEINASE; COMPND 3 CHAIN: B, A; COMPND 4 SYNONYM: 3CL-PRO,3CLP,MAIN PROTEASE,MPRO,NON-STRUCTURAL PROTEIN 5, COMPND 5 NSP5,SARS CORONAVIRUS MAIN PROTEINASE; COMPND 6 EC: 3.4.22.69; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI K-12; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 83333 KEYWDS THE MAIN PROTEASE OF 2019-NCOV COMPLEXED WITH BOCEPREVIR, VIRAL KEYWDS 2 PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR L.F.FU REVDAT 5 29-NOV-23 7BRP 1 REMARK REVDAT 4 10-MAR-21 7BRP 1 COMPND REVDAT 3 25-NOV-20 7BRP 1 JRNL REVDAT 2 04-NOV-20 7BRP 1 COMPND REMARK HET HETNAM REVDAT 2 2 1 HETSYN FORMUL LINK SITE REVDAT 2 3 1 ATOM REVDAT 1 13-MAY-20 7BRP 0 JRNL AUTH L.FU,F.YE,Y.FENG,F.YU,Q.WANG,Y.WU,C.ZHAO,H.SUN,B.HUANG, JRNL AUTH 2 P.NIU,H.SONG,Y.SHI,X.LI,W.TAN,J.QI,G.F.GAO JRNL TITL BOTH BOCEPREVIR AND GC376 EFFICACIOUSLY INHIBIT SARS-COV-2 JRNL TITL 2 BY TARGETING ITS MAIN PROTEASE. JRNL REF NAT COMMUN V. 11 4417 2020 JRNL REFN ESSN 2041-1723 JRNL PMID 32887884 JRNL DOI 10.1038/S41467-020-18233-X REMARK 2 REMARK 2 RESOLUTION. 1.80 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.16_3549 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.80 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 27.57 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 96.9 REMARK 3 NUMBER OF REFLECTIONS : 49507 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.217 REMARK 3 R VALUE (WORKING SET) : 0.216 REMARK 3 FREE R VALUE : 0.240 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.160 REMARK 3 FREE R VALUE TEST SET COUNT : 2557 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 27.5700 - 4.7000 0.98 2734 153 0.1835 0.1941 REMARK 3 2 4.7000 - 3.7400 1.00 2718 169 0.1634 0.1920 REMARK 3 3 3.7400 - 3.2700 1.00 2731 131 0.1922 0.2022 REMARK 3 4 3.2700 - 2.9700 1.00 2692 147 0.2055 0.2168 REMARK 3 5 2.9700 - 2.7600 1.00 2712 132 0.2189 0.2232 REMARK 3 6 2.7600 - 2.5900 1.00 2674 141 0.2339 0.2451 REMARK 3 7 2.5900 - 2.4600 0.99 2664 130 0.2376 0.2564 REMARK 3 8 2.4600 - 2.3600 0.99 2680 132 0.2403 0.2999 REMARK 3 9 2.3600 - 2.2700 1.00 2666 153 0.2332 0.2851 REMARK 3 10 2.2700 - 2.1900 1.00 2648 171 0.2412 0.2703 REMARK 3 11 2.1900 - 2.1200 0.99 2672 120 0.2371 0.2367 REMARK 3 12 2.1200 - 2.0600 1.00 2667 130 0.2434 0.2523 REMARK 3 13 2.0600 - 2.0000 0.99 2709 136 0.2534 0.2775 REMARK 3 14 2.0000 - 1.9600 0.99 2609 157 0.2517 0.2813 REMARK 3 15 1.9600 - 1.9100 0.97 2513 181 0.2559 0.3019 REMARK 3 16 1.9100 - 1.8700 0.93 2513 126 0.2559 0.3257 REMARK 3 17 1.8700 - 1.8300 0.89 2392 141 0.2654 0.3464 REMARK 3 18 1.8300 - 1.8000 0.74 1956 107 0.2719 0.3326 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.216 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 27.572 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 18.17 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 25.30 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 4844 REMARK 3 ANGLE : 1.253 6610 REMARK 3 CHIRALITY : 0.173 748 REMARK 3 PLANARITY : 0.004 852 REMARK 3 DIHEDRAL : 19.288 1716 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN A REMARK 3 ORIGIN FOR THE GROUP (A): 8.6687 -13.6814 15.0037 REMARK 3 T TENSOR REMARK 3 T11: 0.0656 T22: 0.0735 REMARK 3 T33: 0.0833 T12: 0.0228 REMARK 3 T13: 0.0017 T23: 0.0098 REMARK 3 L TENSOR REMARK 3 L11: 0.2370 L22: 0.0990 REMARK 3 L33: 0.5725 L12: -0.0068 REMARK 3 L13: -0.3657 L23: 0.0412 REMARK 3 S TENSOR REMARK 3 S11: -0.0574 S12: -0.0179 S13: -0.0241 REMARK 3 S21: -0.0243 S22: 0.0068 S23: -0.0006 REMARK 3 S31: 0.0475 S32: 0.0717 S33: -0.0962 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN B REMARK 3 ORIGIN FOR THE GROUP (A): 3.1066 -13.1659 40.7656 REMARK 3 T TENSOR REMARK 3 T11: 0.0780 T22: 0.0713 REMARK 3 T33: 0.0920 T12: -0.0066 REMARK 3 T13: -0.0113 T23: 0.0035 REMARK 3 L TENSOR REMARK 3 L11: 0.0570 L22: 0.2736 REMARK 3 L33: 0.6669 L12: 0.1064 REMARK 3 L13: -0.1860 L23: -0.4152 REMARK 3 S TENSOR REMARK 3 S11: -0.0560 S12: 0.0220 S13: -0.0064 REMARK 3 S21: 0.0215 S22: -0.0113 S23: -0.0705 REMARK 3 S31: -0.0234 S32: -0.0061 S33: -0.0948 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7BRP COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 30-MAR-20. REMARK 100 THE DEPOSITION ID IS D_1300016368. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 21-MAR-20 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRF REMARK 200 BEAMLINE : BL17U1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.979 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS EIGER X 16M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 50578 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.800 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 200 DATA REDUNDANCY : 6.000 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 28.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.80 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.86 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 3F9F REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.75 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.04 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% PEG 5000, 0.1M BIS-TRIS, PH 6.5, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 26.77550 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4660 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 24890 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -19.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY B 0 REMARK 465 GLY B 302 REMARK 465 VAL B 303 REMARK 465 THR B 304 REMARK 465 PHE B 305 REMARK 465 GLN B 306 REMARK 465 GLY A 0 REMARK 465 GLY A 302 REMARK 465 VAL A 303 REMARK 465 THR A 304 REMARK 465 PHE A 305 REMARK 465 GLN A 306 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG B 222 CG CD NE CZ NH1 NH2 REMARK 470 ARG A 222 CG CD NE CZ NH1 NH2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OG SER B 144 O HOH B 501 2.12 REMARK 500 O ASN A 274 O HOH A 501 2.14 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN B 51 75.20 -158.40 REMARK 500 ASN B 84 -115.93 53.99 REMARK 500 TYR B 154 -30.74 71.26 REMARK 500 ASP B 155 2.76 -157.68 REMARK 500 ASN A 51 73.38 -158.01 REMARK 500 ASN A 84 -112.89 52.67 REMARK 500 TYR A 154 -157.22 -158.02 REMARK 500 ASP A 155 -7.84 -52.72 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 LEU B 32 ASP B 33 -141.23 REMARK 500 LEU A 32 ASP A 33 -142.49 REMARK 500 TYR A 154 ASP A 155 149.49 REMARK 500 REMARK 500 REMARK: NULL REMARK 630 REMARK 630 MOLECULE TYPE: PEPTIDE-LIKE ENZYME INHIBITOR REMARK 630 MOLECULE NAME: BOCEPREVIR (BOUND FORM) REMARK 630 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 630 SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 630 REMARK 630 M RES C SSSEQI REMARK 630 U5G B 401 REMARK 630 U5G A 401 REMARK 630 SOURCE: NULL REMARK 630 TAXONOMY: NULL REMARK 630 SUBCOMP: TBB TBG 12L 12N NH2 REMARK 630 DETAILS: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue U5G B 401 DBREF 7BRP B 1 306 UNP P0DTC1 R1A_SARS2 3264 3569 DBREF 7BRP A 1 306 UNP P0DTC1 R1A_SARS2 3264 3569 SEQADV 7BRP GLY B 0 UNP P0DTC1 EXPRESSION TAG SEQADV 7BRP GLY A 0 UNP P0DTC1 EXPRESSION TAG SEQRES 1 B 307 GLY SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS SEQRES 2 B 307 VAL GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR SEQRES 3 B 307 THR LEU ASN GLY LEU TRP LEU ASP ASP VAL VAL TYR CYS SEQRES 4 B 307 PRO ARG HIS VAL ILE CYS THR SER GLU ASP MET LEU ASN SEQRES 5 B 307 PRO ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS SEQRES 6 B 307 ASN PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL SEQRES 7 B 307 ILE GLY HIS SER MET GLN ASN CYS VAL LEU LYS LEU LYS SEQRES 8 B 307 VAL ASP THR ALA ASN PRO LYS THR PRO LYS TYR LYS PHE SEQRES 9 B 307 VAL ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA SEQRES 10 B 307 CYS TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA SEQRES 11 B 307 MET ARG PRO ASN PHE THR ILE LYS GLY SER PHE LEU ASN SEQRES 12 B 307 GLY SER CYS GLY SER VAL GLY PHE ASN ILE ASP TYR ASP SEQRES 13 B 307 CYS VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO SEQRES 14 B 307 THR GLY VAL HIS ALA GLY THR ASP LEU GLU GLY ASN PHE SEQRES 15 B 307 TYR GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA SEQRES 16 B 307 GLY THR ASP THR THR ILE THR VAL ASN VAL LEU ALA TRP SEQRES 17 B 307 LEU TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU SEQRES 18 B 307 ASN ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL SEQRES 19 B 307 ALA MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS SEQRES 20 B 307 VAL ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE SEQRES 21 B 307 ALA VAL LEU ASP MET CYS ALA SER LEU LYS GLU LEU LEU SEQRES 22 B 307 GLN ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER ALA SEQRES 23 B 307 LEU LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG SEQRES 24 B 307 GLN CYS SER GLY VAL THR PHE GLN SEQRES 1 A 307 GLY SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS SEQRES 2 A 307 VAL GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR SEQRES 3 A 307 THR LEU ASN GLY LEU TRP LEU ASP ASP VAL VAL TYR CYS SEQRES 4 A 307 PRO ARG HIS VAL ILE CYS THR SER GLU ASP MET LEU ASN SEQRES 5 A 307 PRO ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS SEQRES 6 A 307 ASN PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL SEQRES 7 A 307 ILE GLY HIS SER MET GLN ASN CYS VAL LEU LYS LEU LYS SEQRES 8 A 307 VAL ASP THR ALA ASN PRO LYS THR PRO LYS TYR LYS PHE SEQRES 9 A 307 VAL ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA SEQRES 10 A 307 CYS TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA SEQRES 11 A 307 MET ARG PRO ASN PHE THR ILE LYS GLY SER PHE LEU ASN SEQRES 12 A 307 GLY SER CYS GLY SER VAL GLY PHE ASN ILE ASP TYR ASP SEQRES 13 A 307 CYS VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO SEQRES 14 A 307 THR GLY VAL HIS ALA GLY THR ASP LEU GLU GLY ASN PHE SEQRES 15 A 307 TYR GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA SEQRES 16 A 307 GLY THR ASP THR THR ILE THR VAL ASN VAL LEU ALA TRP SEQRES 17 A 307 LEU TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU SEQRES 18 A 307 ASN ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL SEQRES 19 A 307 ALA MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS SEQRES 20 A 307 VAL ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE SEQRES 21 A 307 ALA VAL LEU ASP MET CYS ALA SER LEU LYS GLU LEU LEU SEQRES 22 A 307 GLN ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER ALA SEQRES 23 A 307 LEU LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG SEQRES 24 A 307 GLN CYS SER GLY VAL THR PHE GLN HET U5G B 401 37 HET U5G A 401 37 HETNAM U5G BOCEPREVIR (BOUND FORM) HETSYN U5G (1R,2S,5S)-N-[(2S,3R)-4-AMINO-1-CYCLOBUTYL-3-HYDROXY-4- HETSYN 2 U5G OXOBUTAN-2-YL]-3-[N-(TERT-BUTYLCARBAMOYL)-3-METHYL-L- HETSYN 3 U5G VALYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXANE-2- HETSYN 4 U5G CARBOXAMIDE FORMUL 3 U5G 2(C27 H47 N5 O5) FORMUL 5 HOH *367(H2 O) HELIX 1 AA1 SER B 10 GLY B 15 1 6 HELIX 2 AA2 HIS B 41 CYS B 44 5 4 HELIX 3 AA3 GLU B 47 ASN B 51 5 5 HELIX 4 AA4 ASN B 53 ARG B 60 1 8 HELIX 5 AA5 SER B 62 PHE B 66 5 5 HELIX 6 AA6 ILE B 200 ASN B 214 1 15 HELIX 7 AA7 THR B 226 TYR B 237 1 12 HELIX 8 AA8 THR B 243 LEU B 250 1 8 HELIX 9 AA9 LEU B 250 GLY B 258 1 9 HELIX 10 AB1 ALA B 260 GLY B 275 1 16 HELIX 11 AB2 THR B 292 CYS B 300 1 9 HELIX 12 AB3 SER A 10 GLY A 15 1 6 HELIX 13 AB4 HIS A 41 CYS A 44 5 4 HELIX 14 AB5 GLU A 47 ASN A 51 5 5 HELIX 15 AB6 ASN A 53 ARG A 60 1 8 HELIX 16 AB7 SER A 62 PHE A 66 5 5 HELIX 17 AB8 ILE A 200 ASN A 214 1 15 HELIX 18 AB9 THR A 226 TYR A 237 1 12 HELIX 19 AC1 THR A 243 LEU A 250 1 8 HELIX 20 AC2 LEU A 250 GLY A 258 1 9 HELIX 21 AC3 ALA A 260 GLY A 275 1 16 HELIX 22 AC4 THR A 292 CYS A 300 1 9 SHEET 1 AA1 7 VAL B 73 LEU B 75 0 SHEET 2 AA1 7 LEU B 67 ALA B 70 -1 N VAL B 68 O LEU B 75 SHEET 3 AA1 7 MET B 17 CYS B 22 -1 N GLN B 19 O GLN B 69 SHEET 4 AA1 7 THR B 25 LEU B 32 -1 O LEU B 27 N VAL B 20 SHEET 5 AA1 7 VAL B 35 PRO B 39 -1 O TYR B 37 N LEU B 30 SHEET 6 AA1 7 VAL B 86 VAL B 91 -1 O LEU B 87 N CYS B 38 SHEET 7 AA1 7 VAL B 77 GLN B 83 -1 N SER B 81 O LYS B 88 SHEET 1 AA2 5 TYR B 101 PHE B 103 0 SHEET 2 AA2 5 CYS B 156 LEU B 167 1 O PHE B 159 N LYS B 102 SHEET 3 AA2 5 VAL B 148 ASP B 153 -1 N ASN B 151 O SER B 158 SHEET 4 AA2 5 THR B 111 TYR B 118 -1 N SER B 113 O PHE B 150 SHEET 5 AA2 5 SER B 121 ALA B 129 -1 O SER B 123 N ALA B 116 SHEET 1 AA3 3 TYR B 101 PHE B 103 0 SHEET 2 AA3 3 CYS B 156 LEU B 167 1 O PHE B 159 N LYS B 102 SHEET 3 AA3 3 VAL B 171 THR B 175 -1 O VAL B 171 N LEU B 167 SHEET 1 AA4 7 VAL A 73 LEU A 75 0 SHEET 2 AA4 7 LEU A 67 ALA A 70 -1 N ALA A 70 O VAL A 73 SHEET 3 AA4 7 MET A 17 CYS A 22 -1 N THR A 21 O LEU A 67 SHEET 4 AA4 7 THR A 25 LEU A 32 -1 O LEU A 27 N VAL A 20 SHEET 5 AA4 7 VAL A 35 PRO A 39 -1 O TYR A 37 N LEU A 30 SHEET 6 AA4 7 VAL A 86 VAL A 91 -1 O LEU A 87 N CYS A 38 SHEET 7 AA4 7 VAL A 77 GLN A 83 -1 N SER A 81 O LYS A 88 SHEET 1 AA5 5 LYS A 100 PHE A 103 0 SHEET 2 AA5 5 CYS A 156 LEU A 167 1 O VAL A 157 N LYS A 100 SHEET 3 AA5 5 VAL A 148 ILE A 152 -1 N ASN A 151 O SER A 158 SHEET 4 AA5 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150 SHEET 5 AA5 5 SER A 121 ALA A 129 -1 O SER A 123 N ALA A 116 SHEET 1 AA6 3 LYS A 100 PHE A 103 0 SHEET 2 AA6 3 CYS A 156 LEU A 167 1 O VAL A 157 N LYS A 100 SHEET 3 AA6 3 VAL A 171 THR A 175 -1 O VAL A 171 N LEU A 167 LINK SG CYS B 145 C03 U5G B 401 1555 1555 1.86 LINK SG CYS A 145 C03 U5G A 401 1555 1555 1.83 SITE 1 AC1 15 HIS B 41 MET B 49 ASN B 142 GLY B 143 SITE 2 AC1 15 SER B 144 CYS B 145 HIS B 164 MET B 165 SITE 3 AC1 15 GLU B 166 ASP B 187 THR B 190 GLN B 192 SITE 4 AC1 15 GLY B 251 PRO B 252 HOH B 641 CRYST1 46.367 53.551 113.772 90.00 101.66 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021567 0.000000 0.004452 0.00000 SCALE2 0.000000 0.018674 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008975 0.00000